Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Trial of Fesoterodine in OAB
NCT00220389Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jun 2003
- Primary completion
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, double-blind trial of fesoterodine in overactive bladder (OAB) (3 arms), sponsored by Pfizer. Primary endpoints: Adverse Events, Residual Urinary Volume and 4 more. Started Jun 2003; status: completed.
02
Drugs
fesoterodine
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT00220389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00220389.